BioCardia Says Based On Interim Results In Autologous CardiAMP Cell Therapy For Treatment Of Heart Failure, Co. Is Exploring Development Of a New Phase 3 Clinical Trial Protocol; CardiAMP HF Trial Showed
Portfolio Pulse from Benzinga Newsdesk
BioCardia, Inc. (NASDAQ:BCDA) is exploring the development of a new Phase III clinical trial protocol for its CardiAMP autologous cell therapy for heart failure treatment, based on recent interim results. The company is considering replacing the third tier 6MWD with a more objective endpoint, potentially leading to a successful trial for product registration in the US. BioCardia is also focusing on accelerating its pivotal program for CardiAMP in Chronic Myocardial Ischemia.
September 06, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCardia's exploration of a new Phase III clinical trial protocol for its CardiAMP cell therapy could potentially lead to a successful trial for product registration in the US. This, along with the acceleration of its program for CardiAMP in Chronic Myocardial Ischemia, could have a positive impact on the company's stock.
The development of a new Phase III clinical trial protocol for BioCardia's CardiAMP cell therapy, based on promising interim results, could potentially lead to a successful trial for product registration in the US. This would be a significant milestone for the company and could positively impact its stock. Additionally, the acceleration of its program for CardiAMP in Chronic Myocardial Ischemia could also contribute to a positive impact on the company's stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100